Targeting lung cancer through inhibition of checkpoint kinases

Frontiers in Genetics

Volumn 5, Issue FEB, 2015, Pages

  Syljuåsen, Randi G ^a   Hasvold, Grete ^a   Hauge, Sissel ^a   Helland, Åslaug ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

ATR; Cancer stem cells; Cancer treatment; Cell cycle checkpoints; Checkpoint abrogation; Chk1; DNA damage; Hypoxia; Inhibitors; Lung cancer; Replication stress; Wee1

Indexed keywords

2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; 5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; ANTINEOPLASTIC AGENT; ATR PROTEIN; B RAF KINASE; CARBOPLATIN; CERITINIB; CHECKPOINT KINASE 1; CISPLATIN; CRIZOTINIB; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MYC PROTEIN; NAVELBINE; PEMETREXED; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE; PROTEIN P53; RAD51 PROTEIN; RAS PROTEIN; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; VE 921; VX 970; WEE1 KINASE;

ARTICLE; CANCER GENETICS; CANCER STEM CELL; CANCER THERAPY; CELL CYCLE CHECKPOINT; CELL CYCLE S PHASE; GENE EXPRESSION; GENE MUTATION; HUMAN; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RECOMBINATION REPAIR; SIGNAL TRANSDUCTION;

EID: 84923622611     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2015.00070     Document Type: Article

References (125)

1. Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., et al. (2006). "Glioma stem cells promote radioresistance by preferential activation of the DNA damage response." Nature 444(7120): 756-760.DOI: 10.1038/nature05236.
2. Bartkova, J., Horejsi, Z., Koed, K., Kramer, A., Tort, F., Zieger, K., et al. (2005). "DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis." Nature 434(7035): 864- 870.DOI: 10.1038/nature03482.
3. Bartucci, M., Svensson, S., Romania, P., Dattilo, R., Patrizii, M., Signore, M., et al. (2012). "Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy." Cell Death Differ 19(5): 768-778.DOI: 10.1038/cdd.2011.170.
4. Beck, H., Nähse-Kumpf, V., Larsen, M. S., O'Hanlon, K. A., Patzke, S., Holmberg, C., et al. (2012). "Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption." Mol Cell Biol 32(20): 4226-4236.DOI: 10.1128/MCB.00412-12.
5. Berge, E. M. and Doebele, R. C. (2014). "Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor." Semin Oncol 41(1): 110- 125.DOI: 10.1053/j.seminoncol.2013.12.006.
6. Bertoni, F., Codegoni, A. M., Furlan, D., Tibiletti, M. G., Capella, C. and Broggini, M. (1999). "CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers." Genes Chromosomes Cancer 26(2): 176-180.
7. Bertout, J. A., Patel, S. A. and Simon, M. C. (2008). "The impact of O2 availability on human cancer." Nat Rev Cancer 8(12): 967-975.DOI: 10.1038/nrc2540.
8. Bertrand, G., Maalouf, M., Boivin, A., Battiston-Montagne, P., Beuve, M., Levy, A., et al. (2014). "Targeting head and neck cancer stem cells to overcome resistance to photon and carbon ion radiation." Stem Cell Rev 10(1): 114-126.DOI: 10.1007/s12015-013-9467-y.
9. Bollineni, V. R., Wiegman, E. M., Pruim, J., Groen, H. J. and Langendijk, J. A. (2012). "Hypoxia imaging using Positron Emission Tomography in non-small cell lung cancer: implications for radiotherapy." Cancer Treat Rev 38(8): 1027-1032.DOI: 10.1016/j.ctrv.2012.04.003.
10. Bonanno, L., Favaretto, A. and Rosell, R. (2014). "Platinum drugs and DNA repair mechanisms in lung cancer." Anticancer Res 34(1): 493-501.
11. Bridges, K. A., Hirai, H., Buser, C. A., Brooks, C., Liu, H., Buchholz, T. A., et al. (2011). "MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells." Clin Cancer Res 17(17): 5638-5648.DOI: 10.1158/1078-0432.CCR-11-0650.
12. Bristow, R. G. and Hill, R. P. (2008). "Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability." Nat Rev Cancer 8(3): 180-192.DOI: 10.1038/nrc2344.
13. Brown, A. D., Sager, B. W., Gorthi, A., Tonapi, S. S., Brown, E. J. and Bishop, A. J. (2014). "ATR suppresses endogenous DNA damage and allows completion of homologous recombination repair." PLoS One 9(3): e91222.DOI: 10.1371/journal.pone.0091222.
14. Brown, E. J. and Baltimore, D. (2000). "ATR disruption leads to chromosomal fragmentation and early embryonic lethality." Genes Dev 14(4): 397-402.
15. Brown, E. J. and Baltimore, D. (2003). "Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance." Genes Dev 17(5): 615-628.DOI: 10.1101/gad.1067403.
16. Brustugun, O. T., Moller, B. and Helland, A. (2014). "Years of life lost as a measure of cancer burden on a national level." Br J Cancer 111(5): 1014-1020.DOI: 10.1038/bjc.2014.364.
17. Butz, H., Liko, I., Czirjak, S., Igaz, P., Khan, M. M., Zivkovic, V., et al. (2010). "Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas." J Clin Endocrinol Metab 95(10): E181-191.DOI: 10.1210/jc.2010-0581.
18. Calvo, E., Chen, V. J., Marshall, M., Ohnmacht, U., Hynes, S. M., Kumm, E., et al. (2014). "Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer." Invest New Drugs 32(5): 955-968.DOI: 10.1007/s10637- 014-0114-5.
19. Carrassa, L., Chila, R., Lupi, M., Ricci, F., Celenza, C., Mazzoletti, M., et al. (2012). "Combined inhibition of Chk1 and Wee1. In vitro synergistic effects translates to tumor growth inhibition in vivo." Cell Cycle 11(13): 2507-2517.DOI: 10.4161/cc.20899.
20. Cazares-Korner, C., Pires, I. M., Swallow, I. D., Grayer, S. C., O'Connor, L. J., Olcina, M. M., et al. (2013). "CH-01 is a hypoxia-activated prodrug that sensitizes cells to hypoxia/reoxygenation through inhibition of Chk1 and Aurora A." ACS Chem Biol 8(7): 1451-1459.DOI: 10.1021/cb4001537.
21. Chaudhuri, L., Vincelette, N. D., Koh, B. D., Naylor, R. M., Flatten, K. S., Peterson, K. L., et al. (2014). "CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo." Haematologica 99(4): 688-696.DOI: 10.3324/haematol.2013.093187.
22. Chen, Z., Fillmore, C. M., Hammerman, P. S., Kim, C. F. and Wong, K. K. (2014). "Non-small-cell lung cancers: a heterogeneous set of diseases." Nat Rev Cancer 14(8): 535-546.DOI: 10.1038/nrc3775.
23. Chia, P. L., Mitchell, P., Dobrovic, A. and John, T. (2014). "Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors." Clin Epidemiol 6: 423-432.DOI: 10.2147/CLEP.S69718.
24. Chila, R., Basana, A., Lupi, M., Guffanti, F., Gaudio, E., Rinaldi, A., et al. (2014). "Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma." Oncotarget. ClinicalTrials.Gov. Cole, K. A., Huggins, J., Laquaglia, M., Hulderman, C. E., Russell, M. R., Bosse, K., et al. (2011). "RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma." Proc Natl Acad Sci U S A 108(8): 3336-3341.DOI: 10.1073/pnas.1012351108.
25. Cole, K. A., Huggins, J., Laquaglia, M., Hulderman, C. E., Russell, M. R., Bosse, K., et al. (2011). "RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma." Proc Natl Acad Sci U S A 108(8): 3336-3341.DOI: 10.1073/pnas.1012351108.
26. Davies, O. R. and Pellegrini, L. (2007). "Interaction with the BRCA2 C terminus protects RAD51- DNA filaments from disassembly by BRC repeats." Nat Struct Mol Biol 14(6): 475-483.DOI: 10.1038/nsmb1251.
27. Dewhirst, M. W. (2009). "Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress." Radiat Res 172(6): 653-665.DOI: 10.1667/RR1926.1.
28. Dixon, H. and Norbury, C. J. (2002). "Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function." Cell Cycle 1(6): 362-368.
29. Do, K., Doroshow, J. H. and Kummar, S. (2013). "Wee1 kinase as a target for cancer therapy." Cell Cycle 12(19): 3159-3164.DOI: 10.4161/cc.26062.
30. Fang, D. D., Cao, J., Jani, J. P., Tsaparikos, K., Blasina, A., Kornmann, J., et al. (2013). "Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line." Front Med 7(4): 462- 476.DOI: 10.1007/s11684-013-0270-6.
31. Forment, J. V., Blasius, M., Guerini, I. and Jackson, S. P. (2011). "Structure-specific DNA endonuclease Mus81/Eme1 generates DNA damage caused by Chk1 inactivation." PLoS One 6(8): e23517.DOI: 10.1371/journal.pone.0023517.
32. Forte, S., Pagliuca, A., Maniscalchi, E. T., Gulino, R., Calabrese, G., Ricci-Vitiani, L., et al. (2013). "Gene expression analysis of PTEN positive glioblastoma stem cells identifies DUB3 and Wee1 modulation in a cell differentiation model." PLoS One 8(12): e81432.DOI: 10.1371/journal.pone.0081432.
33. Friboulet, L., Olaussen, K. A., Pignon, J. P., Shepherd, F. A., Tsao, M. S., Graziano, S., et al. (2013). "ERCC1 isoform expression and DNA repair in non-small-cell lung cancer." New Eng. J. Med. 368(12): 1101-1110.DOI: 10.1056/NEJMoa1214271.
34. Friedel, A. M., Pike, B. L. and Gasser, S. M. (2009). "ATR/Mec1: coordinating fork stability and repair." Curr Opin Cell Biol 21(2): 237-244.DOI: 10.1016/j.ceb.2009.01.017.
35. Froget, B., Blaisonneau, J., Lambert, S. and Baldacci, G. (2008). "Cleavage of stalled forks by fission yeast Mus81/Eme1 in absence of DNA replication checkpoint." Mol Biol Cell 19(2): 445-456.DOI: 10.1091/mbc.E07-07-0728.
36. Gallmeier, E., Hermann, P. C., Mueller, M. T., Machado, J. G., Ziesch, A., De Toni, E. N., et al. (2011). "Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction." Stem Cells 29(3): 418-429.DOI: 10.1002/stem.595.
37. Gilad, O., Nabet, B. Y., Ragland, R. L., Schoppy, D. W., Smith, K. D., Durham, A. C., et al. (2010). "Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner." Cancer Res 70(23): 9693- 9702.DOI: 10.1158/0008-5472.CAN-10-2286.
38. Gomez-Casal, R., Bhattacharya, C., Ganesh, N., Bailey, L., Basse, P., Gibson, M., et al. (2013). "Non small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes." Mol Cancer 12(1): 94.DOI: 10.1186/1476-4598-12-94.
39. Gorgoulis, V. G., Vassiliou, L. V., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., et al. (2005). "Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions." Nature 434(7035): 907-913.DOI: 10.1038/nature03485.
40. Grabauskiene, S., Bergeron, E. J., Chen, G., Chang, A. C., Lin, J., Thomas, D. G., et al. (2013). "CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells." Lung Cancer 82(3): 477-484.DOI: 10.1016/j.lungcan.2013.09.010.
41. Grabocka, E., Commisso, C. and Bar-Sagi, D. (2014). "Molecular Pathways: Targeting the Dependence of Mutant RAS Cancers on the DNA Damage Response." Clin Cancer Res.DOI: 10.1158/1078- 0432.CCR-14-0650.
42. Guertin, A. D., Li, J., Liu, Y., Hurd, M. S., Schuller, A. G., Long, B., et al. (2013). "Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy." Mol Cancer Ther 12(8): 1442-1452.DOI: 10.1158/1535-7163.MCT-13-0025.
43. Halazonetis, T. D., Gorgoulis, V. G. and Bartek, J. (2008). "An oncogene-induced DNA damage model for cancer development." Science 319(5868): 1352-1355.DOI: 10.1126/science.1140735.
44. Hall, A. B., Newsome, D., Wang, Y., Boucher, D. M., Eustace, B., Gu, Y., et al. (2014). "Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970." Oncotarget 5(14): 5674-5685.
45. Hammond, E. M., Denko, N. C., Dorie, M. J., Abraham, R. T. and Giaccia, A. J. (2002). "Hypoxia links ATR and p53 through replication arrest." Mol Cell Biol 22(6): 1834-1843.
46. Hammond, E. M., Dorie, M. J. and Giaccia, A. J. (2003). "ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation." J Biol Chem 278(14): 12207- 12213.DOI: 10.1074/jbc.M212360200.
47. Hammond, E. M., Dorie, M. J. and Giaccia, A. J. (2004). "Inhibition of ATR leads to increased sensitivity to hypoxia/reoxygenation." Cancer Res 64(18): 6556-6562.DOI: 10.1158/0008-5472.CAN- 04-1520.
48. Hasvold, G., Nähse-Kumpf, V., Tkacz-Stachowska, K., Rofstad, E. K. and Syljuåsen, R. G. (2013). "The efficacy of CHK1 inhibitors is not altered by hypoxia, but is enhanced after reoxygenation." Mol Cancer Ther 12(5): 705-716.DOI: 10.1158/1535-7163.MCT-12-0879.
49. Heffernan, T. P., Simpson, D. A., Frank, A. R., Heinloth, A. N., Paules, R. S., Cordeiro-Stone, M., et al. (2002). "An ATR- and Chk1-dependent S checkpoint inhibits replicon initiation following UVC induced DNA damage." Mol Cell Biol 22(24): 8552-8561.
50. Hirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., et al. (2009). "Small molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents." Mol Cancer Ther 8(11): 2992-3000.DOI: 10.1158/1535-7163.MCT-09-0463.
51. Hirokawa, T., Shiotani, B., Shimada, M., Murata, K., Johmura, Y., Haruta, M., et al. (2014). "CBP- 93872 inhibits NBS1-mediated ATR activation, abrogating maintenance of the DNA double-strand break-specific G2 checkpoint." Cancer Res 74(14): 3880-3889.DOI: 10.1158/0008-5472.CAN-13- 3604.
52. Ho, M. M., Ng, A. V., Lam, S. and Hung, J. Y. (2007). "Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells." Cancer Res 67(10): 4827-4833.DOI: 10.1158/0008-5472.CAN-06-3557.
53. Hoglund, A., Nilsson, L. M., Muralidharan, S. V., Hasvold, L. A., Merta, P., Rudelius, M., et al. (2011). "Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells." Clin Cancer Res 17(22): 7067-7079.DOI: 10.1158/1078-0432.CCR-11-1198.
54. Horsman, M. R., Mortensen, L. S., Petersen, J. B., Busk, M. and Overgaard, J. (2012). "Imaging hypoxia to improve radiotherapy outcome." Nat Rev Clin Oncol 9(12): 674-687.DOI: 10.1038/nrclinonc.2012.171. http://cancergenome.broadinstitute.org.
55. Iorns, E., Lord, C. J., Grigoriadis, A., McDonald, S., Fenwick, K., Mackay, A., et al. (2009). "Integrated functional, gene expression and genomic analysis for the identification of cancer targets." PLoS One 4(4): e5120.DOI: 10.1371/journal.pone.0005120.
56. Jeggo, P. A., Geuting, V. and Lobrich, M. (2011). "The role of homologous recombination in radiation induced double-strand break repair." Radiother Oncol 101(1): 7-12.DOI: 10.1016/j.radonc.2011.06.019.
57. Keysar, S. B. and Jimeno, A. (2010). "More than markers: biological significance of cancer stem cell defining molecules." Mol Cancer Ther 9(9): 2450-2457.DOI: 10.1158/1535-7163.MCT-10-0530.
58. Krajewska, M., Fehrmann, R. S., Schoonen, P. M., Labib, S., de Vries, E. G., Franke, L., et al. (2014). ATR inhibition preferentially targets homologous recombination-deficient tumor cells." Oncogene.DOI: 10.1038/onc.2014.276.
59. Krajewska, M., Heijink, A. M., Bisselink, Y. J., Seinstra, R. I., Sillje, H. H., de Vries, E. G., et al. 2013). "Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination." Oncogene 32(24): 3001-3008.DOI: 10.1038/onc.2012.296.
60. Lecona, E. and Fernandez-Capetillo, O. (2014). "Replication stress and cancer: It takes two to tango." Exp Cell Res.DOI: 10.1016/j.yexcr.2014.09.019.
61. Leijen, S., Beijnen, J. H. and Schellens, J. H. (2010). "Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents." Curr Clin Pharmacol 5(3): 186-191.
62. Leung, E. L., Fiscus, R. R., Tung, J. W., Tin, V. P., Cheng, L. C., Sihoe, A. D., et al. (2010). "Non small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties." PLoS One 5(11): e14062.DOI: 10.1371/journal.pone.0014062.
63. Lewis, K. A., Mullany, S., Thomas, B., Chien, J., Loewen, R., Shridhar, V., et al. (2005). Heterozygous ATR mutations in mismatch repair-deficient cancer cells have functional significance." Cancer Res 65(16): 7091-7095.DOI: 10.1158/0008-5472.CAN-05-1019.
64. Little, C. D., Nau, M. M., Carney, D. N., Gazdar, A. F. and Minna, J. D. (1983). "Amplification and expression of the c-myc oncogene in human lung cancer cell lines." Nature 306(5939): 194-196.
65. Liu, Q., Guntuku, S., Cui, X. S., Matsuoka, S., Cortez, D., Tamai, K., et al. (2000). "Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint." Genes Dev 14(12): 1448-1459.
66. Llona-Minguez, S., Hoglund, A., Jacques, S. A., Koolmeister, T. and Helleday, T. (2014). "Chemical strategies for development of ATR inhibitors." Expert Rev Mol Med 16: e10.DOI: 10.1017/erm.2014.10.
67. Lopez-Contreras, A. J., Gutierrez-Martinez, P., Specks, J., Rodrigo-Perez, S. and Fernandez-Capetillo, O. (2012). "An extra allele of Chk1 limits oncogene-induced replicative stress and promotes transformation." J Exp Med 209(3): 455-461.DOI: 10.1084/jem.20112147.
68. Lund-Andersen, C., Patzke, S., Nähse-Kumpf, V. and Syljuåsen, R. G. (2014). "PLK1-inhibition can cause radiosensitization or radioresistance dependent on the treatment schedule." Radiother Oncol 110(2): 355-361.DOI: 10.1016/j.radonc.2013.12.014.
69. Lundholm, L., Haag, P., Zong, D., Juntti, T., Mork, B., Lewensohn, R., et al. (2013). "Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA PK/ATM activation and diminished cell cycle arrest." Cell Death Dis 4: e478.DOI: 10.1038/cddis.2012.211.
70. Luo, Z., Wu, R. R., Lv, L., Li, P., Zhang, L. Y., Hao, Q. L., et al. (2014). "Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review." Int J Clin Exp Pathol 7(7): 3632-3646.
71. Luoto, K. R., Kumareswaran, R. and Bristow, R. G. (2013). "Tumor hypoxia as a driving force in genetic instability." Genome Integr 4(1): 5.DOI: 10.1186/2041-9414-4-5.
72. Ma, C. X., Janetka, J. W. and Piwnica-Worms, H. (2011). "Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics." Trends Mol Med 17(2): 88-96.
73. Magnussen, G. I., Holm, R., Emilsen, E., Rosnes, A. K., Slipicevic, A. and Florenes, V. A. (2012). High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy." PLoS One 7(6): e38254.DOI: 10.1371/journal.pone.0038254.
74. McCord, A. M., Jamal, M., Williams, E. S., Camphausen, K. and Tofilon, P. J. (2009). "CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines." Clin Cancer Res 15(16): 5145-5153.DOI: 10.1158/1078-0432.CCR-09-0263.
75. McNeely, S., Beckmann, R. and Bence Lin, A. K. (2014). "CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy." Pharmacol Ther 142(1): 1-10.DOI: 10.1016/j.pharmthera.2013.10.005.
76. Melosky, B. (2014). "Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials." Front Oncol 4: 244.DOI: 10.3389/fonc.2014.00244.
77. Mir, S. E., De Witt Hamer, P. C., Krawczyk, P. M., Balaj, L., Claes, A., Niers, J. M., et al. (2010). "In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma." Cancer Cell 18(3): 244-257.DOI: 10.1016/j.ccr.2010.08.011.
78. Mohni, K. N., Kavanaugh, G. M. and Cortez, D. (2014). "ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency." Cancer Res 74(10): 2835-2845.DOI: 10.1158/0008- 5472.CAN-13-3229.
79. Morgan, M. A., Parsels, L. A., Zhao, L., Parsels, J. D., Davis, M. A., Hassan, M. C., et al. (2010). "Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair." Cancer Res 70(12): 4972- 4981.DOI: 10.1158/0008-5472.CAN-09-3573.
80. Murga, M., Campaner, S., Lopez-Contreras, A. J., Toledo, L. I., Soria, R., Montana, M. F., et al. (2011). "Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors." Nat Struct Mol Biol 18(12): 1331-1335.DOI: 10.1038/nsmb.2189.
81. Nagasawa, H., Li, C. Y., Maki, C. G., Imrich, A. C. and Little, J. B. (1995). "Relationship between radiation-induced G1 phase arrest and p53 function in human tumor cells." Cancer Res 55(9): 1842- 1846.
82. O'Connor, M. L., Xiang, D., Shigdar, S., Macdonald, J., Li, Y., Wang, T., et al. (2014). "Cancer stem cells: A contentious hypothesis now moving forward." Cancer Lett 344(2): 180-187.DOI: 10.1016/j.canlet.2013.11.012.
83. O'Brien, E., Senra, J., Anbalagan, S., Hill, M. and Hammond, E. (2013). "Impact of Wee1 inhibition on the hypoxia-induced DNA damage response." Tumor Microenvironment and Therapy 1: 37-45.
84. Olcina, M., Lecane, P. S. and Hammond, E. M. (2010). "Targeting hypoxic cells through the DNA damage response." Clin Cancer Res 16(23): 5624-5629.DOI: 10.1158/1078-0432.CCR-10-0286.
85. Parikh, R. A., Appleman, L. J., Bauman, J. E., Sankunny, M., Lewis, D. W., Vlad, A., et al. (2014). "Upregulation of the ATR-CHEK1 pathway in oral squamous cell carcinomas." Genes Chromosomes Cancer 53(1): 25-37.DOI: 10.1002/gcc.22115.
86. Parker, L. L. and Piwnica-Worms, H. (1992). "Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase." Science 257(5078): 1955-1957.
87. Petersen, L., Hasvold, G., Lukas, J., Bartek, J. and Syljuåsen, R. G. (2010). "p53-dependent G(1) arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionizing radiation and Chk1 inhibitors." Cell Prolif 43(4): 365-371.DOI: 10.1111/j.1365-2184.2010.00685.x.
88. Pires, I. M., Olcina, M. M., Anbalagan, S., Pollard, J. R., Reaper, P. M., Charlton, P. A., et al. (2012). "Targeting radiation-resistant hypoxic tumour cells through ATR inhibition." Br J Cancer 107(2): 291- 299.DOI: 10.1038/bjc.2012.265.
89. Postel-Vinay, S., Vanhecke, E., Olaussen, K. A., Lord, C. J., Ashworth, A. and Soria, J. C. (2012). "The potential of exploiting DNA-repair defects for optimizing lung cancer treatment." Nat Rev Clin Oncol 9(3): 144-155.DOI: 10.1038/nrclinonc.2012.3.
90. Reaper, P. M., Griffiths, M. R., Long, J. M., Charrier, J. D., Maccormick, S., Charlton, P. A., et al. (2011). "Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR." Nat Chem Biol 7(7): 428-430.DOI: 10.1038/nchembio.573.
91. Ropolo, M., Daga, A., Griffero, F., Foresta, M., Casartelli, G., Zunino, A., et al. (2009). "Comparative analysis of DNA repair in stem and nonstem glioma cell cultures." Mol Cancer Res 7(3): 383-392.DOI: 10.1158/1541-7786.MCR-08-0409.
92. Russell, M. R., Levin, K., Rader, J., Belcastro, L., Li, Y., Martinez, D., et al. (2013). "Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma." Cancer Res 73(2): 776-784.DOI: 10.1158/0008-5472.CAN-12-2669.
93. Salcido, C. D., Larochelle, A., Taylor, B. J., Dunbar, C. E. and Varticovski, L. (2010). "Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer." Br J Cancer 102(11): 1636-1644.DOI: 10.1038/sj.bjc.6605668.
94. Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms, H., et al. (1997). "Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25." Science 277(5331): 1497-1501.
95. Sarcar, B., Kahali, S., Prabhu, A. H., Shumway, S. D., Xu, Y., Demuth, T., et al. (2011). "Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines." Mol Cancer Ther 10(12): 2405-2414.DOI: 10.1158/1535-7163.MCT-11-0469.
96. Sausville, E., Lorusso, P., Carducci, M., Carter, J., Quinn, M. F., Malburg, L., et al. (2014). "Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors." Cancer Chemother Pharmacol 73(3): 539-549.DOI: 10.1007/s00280-014-2380-5.
97. Schoppy, D. W., Ragland, R. L., Gilad, O., Shastri, N., Peters, A. A., Murga, M., et al. (2012). "Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR." J Clin Invest 122(1): 241-252.DOI: 10.1172/JCI58928.
98. Siegel, R., Naishadham, D. and Jemal, A. (2012). "Cancer statistics, 2012." CA Cancer J Clin 62(1): 10-29.DOI: 10.3322/caac.20138.
99. Signore, M., Pelacchi, F., di Martino, S., Runci, D., Biffoni, M., Giannetti, S., et al. (2014). "Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo." Cell Death Dis 5: e1223.DOI: 10.1038/cddis.2014.188.
100. Singh, S. and Chellappan, S. (2014). "Lung cancer stem cells: Molecular features and therapeutic targets." Mol Aspects Med 39: 50-60.DOI: 10.1016/j.mam.2013.08.003.
101. Syljuåsen, R. G., Sørensen, C. S., Hansen, L. T., Fugger, K., Lundin, C., Johansson, F., et al. (2005). "Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage." Mol Cell Biol 25(9): 3553-3562.DOI: 25/9/3553 [pii] 10.1128/MCB.25.9.3553-3562.2005.
102. Syljuåsen, R. G., Sørensen, C. S., Nylandsted, J., Lukas, C., Lukas, J. and Bartek, J. (2004). "Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation." Cancer Res 64(24): 9035-9040.DOI: 10.1158/0008-5472.CAN-04-2434.
103. Sørensen, C. S., Hansen, L. T., Dziegielewski, J., Syljuåsen, R. G., Lundin, C., Bartek, J., et al. (2005). "The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair." Nat Cell Biol 7(2): 195-201.DOI: 10.1038/ncb1212.
104. Sørensen, C. S. and Syljuåsen, R. G. (2012). "Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication." Nucleic Acids Res 40(2): 477-486.
105. Sørensen, C. S., Syljuåsen, R. G., Falck, J., Schroeder, T., Ronnstrand, L., Khanna, K. K., et al. (2003). "Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation induced accelerated proteolysis of Cdc25A." Cancer Cell 3(3): 247-258.
106. Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., et al. (1989). "p53: a frequent target for genetic abnormalities in lung cancer." Science 246(4929): 491-494.
107. Tili, E., Michaille, J. J., Wernicke, D., Alder, H., Costinean, S., Volinia, S., et al. (2011). "Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer." Proc Natl Acad Sci U S A 108(12): 4908-4913.DOI: 10.1073/pnas.1101795108.
108. Toledo, L. I., Altmeyer, M., Rask, M. B., Lukas, C., Larsen, D. H., Povlsen, L. K., et al. (2013). "ATR prohibits replication catastrophe by preventing global exhaustion of RPA." Cell 155(5): 1088- 1103.DOI: 10.1016/j.cell.2013.10.043.
109. Toledo, L. I., Murga, M. and Fernandez-Capetillo, O. (2011). "Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs." Mol Oncol 5(4): 368-373.DOI: 10.1016/j.molonc.2011.07.002.
110. Tominaga, Y., Li, C., Wang, R. H. and Deng, C. X. (2006). "Murine Wee1 plays a critical role in cell cycle regulation and pre-implantation stages of embryonic development." Int J Biol Sci 2(4): 161-170.
111. Vasan, N., Boyer, J. L. and Herbst, R. S. (2014). "A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer." Clin Cancer Res 20(15): 3921-3930.DOI: 10.1158/1078- 0432.CCR-13-1762.
112. Venkatesha, V. A., Parsels, L. A., Parsels, J. D., Zhao, L., Zabludoff, S. D., Simeone, D. M., et al. (2012). "Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition." Neoplasia 14(6): 519-525.
113. Walsh, J. C., Lebedev, A., Aten, E., Madsen, K., Marciano, L. and Kolb, H. C. (2014). "The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities." Antioxid Redox Signal 21(10): 1516-1554.DOI: 10.1089/ars.2013.5378.
114. Wang, X., Ma, Z., Xiao, Z., Liu, H., Dou, Z., Feng, X., et al. (2012). "Chk1 knockdown confers radiosensitization in prostate cancer stem cells." Oncol Rep 28(6): 2247-2254.DOI: 10.3892/or.2012.2068.
115. Wang, Y., Li, J., Booher, R. N., Kraker, A., Lawrence, T., Leopold, W. R., et al. (2001). "Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator." Cancer Res 61(22): 8211-8217.
116. Wei, H. B., Hu, J., Shang, L. H., Zhang, Y. Y., Lu, F. F., Wei, M., et al. (2012). "A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer." Chin Med J (Engl) 125(16): 2902-2907.
117. Weisberg, E., Nonami, A., Chen, Z., Liu, F., Zhang, J., Sattler, M., et al. (2014). "Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies." Leukemia.DOI: 10.1038/leu.2014.149.
118. Willers, H., Azzoli, C. G., Santivasi, W. L. and Xia, F. (2013). "Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer." Cancer J 19(3): 200-207.DOI: 10.1097/PPO.0b013e318292e4e3.
119. Wu, H., Qi, X. W., Yan, G. N., Zhang, Q. B., Xu, C. and Bian, X. W. (2014). "Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis." PLoS One 9(6): e100168.DOI: 10.1371/journal.pone.0100168.
120. Wu, J., Lai, G., Wan, F., Xiao, Z., Zeng, L., Wang, X., et al. (2012). "Knockdown of checkpoint kinase 1 is associated with the increased radiosensitivity of glioblastoma stem-like cells." Tohoku J Exp Med 226(4): 267-274.
121. Xiao, H. H., Makeyev, Y., Butler, J., Vikram, B. and Franklin, W. A. (2002). "7-Hydroxystaurosporine (UCN-01) preferentially sensitizes cells with a disrupted TP53 to gamma radiation in lung cancer cell lines." Radiat Res 158(1): 84-93.
122. Yang, H., Yoon, S. J., Jin, J., Choi, S. H., Seol, H. J., Lee, J. I., et al. (2011). "Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy." Biochem Biophys Res Commun 406(1): 53-58.DOI: 10.1016/j.bbrc.2011.01.106.
123. Yoshida, T., Tanaka, S., Mogi, A., Shitara, Y. and Kuwano, H. (2004). "The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer." Ann Oncol 15(2): 252-256.
124. Zhao, H. and Piwnica-Worms, H. (2001). "ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1." Mol Cell Biol 21(13): 4129-4139.DOI: 10.1128/MCB.21.13.4129-4139.2001.
125. Zighelboim, I., Schmidt, A. P., Gao, F., Thaker, P. H., Powell, M. A., Rader, J. S., et al. (2009). "ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes." J Clin Oncol 27(19): 3091-3096.DOI: 10.1200/JCO.2008.19.9802.